One of Australia’s most promising biotech companies has laid off 10 per cent of its workforce and is searching for a new chief executive after a challenging capital raising campaign fell short of expectations.
Brisbane start-up Vaxxas, which is working to replace the flu jab with a vaccine patch, has raised $50 million in equity and secured a new $40 million debt facility to continue developing technology that can deliver vaccines without utilizing syringes.
Loading…
Leave a Reply